Default company panoramic image
Logo

Merganser Biotech LLC

An early stage biotech company that is looking for investment to develop a novel therapy for rare hematological diseases

  • Stage Product In Development
  • Industry Biotechnology
  • Location United States
  • Currency USD
  • Founded February 2011
  • Employees 0

Company Summary

Merganser was founded by experienced biotech executives and develops novel therapies for orphan diseases. We operate a virtual project based model and take projects from preclinical to clinical proof of concept. Careful project selection ensures that our projects are attractive to big pharma or big biotech partners. We are currently working on novel hepcidin mimetic peptides for the treatment of rare hematological diseases.

Team

  • Default avatar
    Brian MacDonald
    Dr

    A highly effective MD, PhD biopharmaceutical executive with extensive drug development experience. Appointed as CEO of Zelos Therapeutics in October 2005. Raised >$40 million in equity and debt financing while at Zelos. Previously served as first Head of Development for 3-Dimensional Pharmaceuticals (acquired by J&J in 2003). Preclinical through Phase IV drug development experience with GlaxoSmithKline

Advisors

  • Default avatar
    David Sharrow: Partner, Gunderson Dettmer
    Lawyer
    Unconfirmed
    Default avatar
    Lisa Carson, Carson Consulting
    Accountant
    Unconfirmed

Previous Investors

  • Default avatar
    BioAdvance: Biotechnology Greenhouse Corp of SE Pennsylvania
    Unconfirmed
    Default avatar
    Stateside Development LLC
    Unconfirmed
    Default avatar
    Management
    Unconfirmed